Corcept Therapeutics is a commercial-stage company engaged in the discovery and development of medications that treat severe metabolic, oncologic and psychiatric disorders by modulating the effect of the hormone cortisol. The U.S. Food and Drug Administration has approved Korlym? 300 mg tablets, as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company has discovered and patented four structurally series of selective cortisol modulators, consisting a variety of compounds.